Tharimmune Stock Operating Margin
| THAR Stock | 2.21 0.13 6.25% |
Tharimmune fundamentals help investors to digest information that contributes to Tharimmune's financial success or failures. It also enables traders to predict the movement of Tharimmune Stock. The fundamental analysis module provides a way to measure Tharimmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tharimmune stock.
| Last Reported | Projected for Next Year |
Tharimmune | Operating Margin |
Tharimmune Company Operating Margin Analysis
Tharimmune's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Tharimmune Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Tharimmune is extremely important. It helps to project a fair market value of Tharimmune Stock properly, considering its historical fundamentals such as Operating Margin. Since Tharimmune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tharimmune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tharimmune's interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Tharimmune has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Tharimmune Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tharimmune's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tharimmune could also be used in its relative valuation, which is a method of valuing Tharimmune by comparing valuation metrics of similar companies.Tharimmune is currently under evaluation in operating margin category among its peers.
Tharimmune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tharimmune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tharimmune's managers, analysts, and investors.Environmental | Governance | Social |
Tharimmune Fundamentals
| Return On Equity | -4.55 | ||||
| Return On Asset | -1.65 | ||||
| Current Valuation | 81.67 K | ||||
| Shares Outstanding | 1.49 M | ||||
| Shares Owned By Insiders | 1.79 % | ||||
| Shares Owned By Institutions | 1.63 % | ||||
| Number Of Shares Shorted | 95.63 K | ||||
| Price To Book | 1.02 X | ||||
| EBITDA | (9.3 M) | ||||
| Net Income | (9.32 M) | ||||
| Total Debt | 1.82 M | ||||
| Book Value Per Share | 2.35 X | ||||
| Cash Flow From Operations | (7.3 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | 61.01 X | ||||
| Target Price | 4.0 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 3.36 M | ||||
| Total Asset | 10.95 M | ||||
| Retained Earnings | (24.7 M) | ||||
| Working Capital | 9.13 M | ||||
| Net Asset | 10.95 M |
About Tharimmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tharimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tharimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tharimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Tharimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tharimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tharimmune will appreciate offsetting losses from the drop in the long position's value.Moving against Tharimmune Stock
| 0.35 | DMAC | DiaMedica Therapeutics Downward Rally | PairCorr |
The ability to find closely correlated positions to Tharimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tharimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tharimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tharimmune to buy it.
The correlation of Tharimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tharimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tharimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tharimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.